1990
DOI: 10.1590/s0074-02761990000400021
|View full text |Cite
|
Sign up to set email alerts
|

Use of Trypanosoma cruzi defined proteins for diagnosis-multicentre trial: serological and technical aspects

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
14
0
3

Year Published

1991
1991
2014
2014

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 29 publications
(17 citation statements)
references
References 0 publications
0
14
0
3
Order By: Relevance
“…In Latin America, the most commonly tests for screening, and sometimes for confirmation, are the enzyme immunoassays using conventional (crude antigens) or non conventional reagents (mixture of peptides or recombinant antigens) (Luquetti 1990, Ferreira et al 2001, Umezawa et al 2003. The IHA is also used for screening and, on occasions, as a second test for confirmation.…”
Section: Preventionmentioning
confidence: 99%
“…In Latin America, the most commonly tests for screening, and sometimes for confirmation, are the enzyme immunoassays using conventional (crude antigens) or non conventional reagents (mixture of peptides or recombinant antigens) (Luquetti 1990, Ferreira et al 2001, Umezawa et al 2003. The IHA is also used for screening and, on occasions, as a second test for confirmation.…”
Section: Preventionmentioning
confidence: 99%
“…The use of purified antigen for the conclusive and reliable diagnosis of Chagas' disease has been emphasized as being of paramount importance among the different issues currently under study concerning this parasitosis [10,11].…”
Section: Introductionmentioning
confidence: 99%
“…The World Health Organization has long emphasized the need for defined antigens to improve serodiagnosis of Chagas' disease. In an attempt to solve this problem, several research groups have used recombinant and/or synthetic and biochemically purified antigens (1,7,12,(14)(15)(16)19). In order to be useful, these antigens must meet the following criteria: (i) they should be present in T. cruzi isolates from different areas of endemicity and absent in other infectious disease agents; (ii) they should be highly immunogenic in populations with different immunogenetic backgrounds, regardless of the clinical phase of Chagas' disease; and (iii) they should be stable and easily amenable to quality control tests, to guarantee reproducibility (18,24).…”
mentioning
confidence: 99%